Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Differences between Alzheimer’s disease biomarkers: p-Tau181, p-Tau231 & p-Tau217

Nicholas Ashton, PhD, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden and King’s College London, London, UK, compares promising Alzheimer’s disease biomarkers. In clinical practice, there is very little difference between p-Tau181, p-Tau231, and p-Tau217; it is more about the quality of the assay. Early evidence suggests that p-Tau231 emerges earlier in patients with no symptoms but emerging pathology – this subtle difference may be meaningful in large population screenings. p-Tau217 also may be more specific for Alzheimer’s disease pathology and thus depict it more quickly. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.